Table 1 Baseline characteristics of patients in the three cohorts stratified by MRI response and treatment regimens

From: Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): efficacy, safety and biomarker analysis of a prospective, multicentre, response-adapted study

Characteristics

Patients (N = 129)

P

Cohort A (n = 62)

Cohort B (n = 26)

Cohort C (n = 41)

Median age of years (range)

50.0 (43.2–54.8)

52.5 (47.2–59.8)

50.0 (44.0–54.0)

0.15

Menopausal status, n (%)

   

0.21

 Postmenopausal

30 (48.4)

17 (65.4)

18 (43.9)

 

 Premenopausal

32 (51.6)

9 (34.6)

23 (56.1)

 

Clinical T stage, n (%)

   

0.94

 T1

6 (9.7)

2 (7.7)

4 (9.8)

 

 T2

50 (80.6)

19 (73.1)

31 (75.6)

 

 T3

4 (6.5)

3 (11.5)

4 (9.8)

 

 T4

2 (3.2)

2 (7.7)

2 (4.9)

 

Lymph node status, n (%)

   

0.27

 N0

22 (35.5)

12 (46.2)

19 (46.3)

 

 N1

32 (51.6)

8 (30.8)

13 (31.7)

 

 N2

7 (11.3)

5 (19.2)

9 (22.0)

 

 N3

1 (1.6)

1 (3.8)

0 (0.0)

 

TNM status, n (%)

   

0.57

 II

45 (72.6)

16 (61.5)

30 (73.2)

 

 III

17 (27.4)

10 (38.5)

11 (26.8)

 

HR status, n (%)

   

0.40

 ER+ and/or PR+

42 (67.7)

20 (76.9)

25 (61.0)

 

 ER- and PR-

20 (32.3)

6 (23.1)

16 (39.0)

 

HER2 status, n (%)

   

0.16

 HER2 (IHC score 3+)

55 (88.7)

25 (96.2)

33 (80.5)

 

 HER2 (IHC score 2+)

7 (11.3)

1 (3.8)

8 (19.5)

 

Ki67 level, n (%)

   

0.62

 <20%

11 (17.7)

7 (26.9)

9 (22.0)

 

 ≥20%

51 (82.3)

19 (73.1)

32 (78.0)

 
  1. HR hormone receptor, ER+ estrogen receptor-positive, ER- estrogen receptor-negative, PR+ progesterone receptor-positive, PR- progesterone receptor-negative, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry
Back to article page